Plain-English translation of NCT06610734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called combined with and low-dose radiation therapy for people with extensive-stage small cell lung cancer — a serious form of lung cancer that has spread. The study compares two approaches: one group receives the medication with and radiation together, while the other group receives the medication with alone. Researchers want to see which combination works best and is safest.
Small cell lung cancer is an aggressive cancer, and existing treatments don't work well enough for many patients. This study explores whether this new immune-boosting medication can help the body fight the cancer more effectively when combined with standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two treatment groups. Both groups receive the new medication along with ; one group also receives low-dose radiation therapy to the chest at the same time. You will visit the clinic regularly for treatment, blood tests, and scans to monitor how you're responding. The study involves multiple hospitals, so you may be enrolled at a center near you.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China